has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role therapeutic cancer vaccine MUC1 peptide-poly-ICLC vaccine cancer vaccine Hayleigh Kahn NCT: https://clinicaltrials.gov/study/NCT03300817 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6316 Gene name: MUC-1 A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer. 6316 4582 NCT: https://clinicaltrials.gov/study/NCT00986609 Jie Zheng NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417